AURX Stock Overview

A regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. More details

AURX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 39.5% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the US market

Does not have meaningful revenue ($1M)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Nuo Therapeutics, Inc. Competitors

Kronos Bio

NasdaqGS:KRON

US$55.5m

Kezar Life Sciences

NasdaqCM:KZR

US$49.9m

Generation Bio

NasdaqGS:GBIO

US$74.1m

Vaxart

NasdaqCM:VXRT

US$138.3m

Price History & Performance

Summary of share price highs, lows and changes for Nuo Therapeutics
Historical stock prices
Current Share Price	US$1.53
52 Week High	US$1.76
52 Week Low	US$0.25
Beta	-740.81
1 Month Change	50.25%
3 Month Change	189.15%
1 Year Change	178.64%
3 Year Change	1,532,400.00%
5 Year Change	1,177.08%
Change since IPO	-23.38%

Recent updates

Shareholder Returns

	AURX	US Biotechs	US Market
7D	-1.1%	0.7%	0.6%
1Y	178.6%	-3.4%	23.8%

Return vs Industry: AURX exceeded the US Biotechs industry which returned -3.4% over the past year.

Return vs Market: AURX exceeded the US Market which returned 23.8% over the past year.

Price Volatility

Is AURX's price volatile compared to industry and market?
AURX volatility
AURX Average Weekly Movement	21.0%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AURX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AURX's weekly volatility has decreased from 31% to 21% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1998	9	David Jorden	www.nuot.com

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds.

Nuo Therapeutics, Inc. Fundamentals Summary

How do Nuo Therapeutics's earnings and revenue compare to its market cap?
AURX fundamental statistics
Market cap	US$71.75m
Earnings (TTM)	-US$2.48m
Revenue (TTM)	US$1.17m

61.5x

P/S Ratio

-28.9x

P/E Ratio

Is AURX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AURX income statement (TTM)
Revenue	US$1.17m
Cost of Revenue	US$257.80k
Gross Profit	US$909.52k
Other Expenses	US$3.39m
Earnings	-US$2.48m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.053
Gross Margin	77.92%
Net Profit Margin	-212.47%
Debt/Equity Ratio	0%

How did AURX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/28 07:55
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nuo Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Napodano	Zacks Investment Research Inc.